Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 30, 2015 2:25 AM ET


Company Overview of SanBio, Inc.

Company Overview

SanBio, Inc. develops regenerative therapies for neurological disorders. Its product pipeline includes SB623, which integrates into the tissue and reverses neural damage; SB618 for the treatment of conditions that affect the myelin sheath of neurons, such as multiple sclerosis and spinal cord injury; and SB308, which uses donor bone marrow to create muscle progenitor cells. The company’s products are used for the treatment of various neurological disorders, including stroke, spinal cord injury, Parkinson's disease, and multiple sclerosis. SanBio, Inc. was founded in 2001 and is based in Mountain View, California. SanBio, Inc. operates as a subsidiary of SanBio Company Limited.

231 South Whisman Road

Mountain View, CA 94041-1522

United States

Founded in 2001





Key Executives for SanBio, Inc.

Co-Founder, Chairman and Co- Chief Executive Officer
Age: 48
Co-Founder, Co- Chief Executive Officer and Director
Age: 48
Senior Vice President of Production Development
Chief Medical Officer and Head of Research
Compensation as of Fiscal Year 2015.

SanBio, Inc. Key Developments

Sanbio Inc. Begins Recruiting Patients to Test Regenerative Treatment for Traumatic Brain Injury

SanBio Inc. announced that it has opened patient recruitment for its Phase 2 clinical trial study to evaluate the clinical efficacy and safety of its proprietary cell therapy following traumatic brain injury (TBI). In the United States alone, more than 5.3 million people live with disabilities caused by TBI - with approximately 1.5 million people suffering from such an injury each year. The effects can be devastating, often requiring long-term rehabilitation and care to overcome severe neurological deficits, including cognitive and motor-function impairment. The Phase 2 clinical trial follows a Phase 1/2a clinical trial in patients with chronic motor deficit secondary to ischemic stroke, which showed statistically significant improvements in motor function following implantation of SB623 cells. The Phase 2 study will further evaluate the efficacy and safety of the treatment, as well as the safety and tolerability of the administration process. Patients must be between 12-36 months post injury. The study will be conducted across approximately 20 clinical trial sites throughout the United States. Total enrollment is expected to reach 52 patients.

SanBio, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

SanBio, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

SanBio, Inc. Presents at BIO-Europe 2014, Nov-04-2014 03:00 PM

SanBio, Inc. Presents at BIO-Europe 2014, Nov-04-2014 03:00 PM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany.

Similar Private Companies By Industry

Company Name Region
Revolution Bioengineering, LLC United States
Cell Signaling Technology, Inc. United States
Regulon Inc. United States
SweetBio, Inc. United States
Applied Veterinary Systems United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SanBio, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at